Ongoing clinical trials of anti-platelet agents in the management of acute ischaemic coronary syndromes

Bibliography

• WHITE HD: Unmet therapeutic needs in the manage-ment of acute ischemia. Am. J. Cardiol. (1997) 80(4A) :2B–10B.
   Google Scholar
• FUSTER V: Mechanisms leading to myocardial infarc-tion: insights from studies of vascular biology. Circula-tion (1994) 90:2126–2146.
   PubMed Web of Science ®Google Scholar
• FUSTER V, BADIMON L, BADIMON JJ, CHESEBRO JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl. J. Med. (1992) 326:242-250, 310–318.
   PubMedGoogle Scholar
• ••Seminal review of current pathological concepts of the acutecoronary syndromes.
   Google Scholar
• ANTIPLATELET TRIALISTS' COLLABORATION: Collabora- tive overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in vari-ous categories of patients. Br. Med. J. (1994) 308:81–106.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ: A macro and micro view of coronary vascu-lar insult in ischaemic heart disease. Circulation (1990) 82 (Suppl.) :II-38-11–46.
   Google Scholar
• LEBRETON H, PLOW EF, TOPOL EJ: Role of platelets in restenosis after percutaneous coronary revasculariza-tion. J. Am. Coll. Cardiol. (1996) 28:1643–1651.
   PubMed Web of Science ®Google Scholar
• SCHAFFER Al: Antiplatelet therapy. Am. J. Med. (1996) 101:199–209.
   PubMed Web of Science ®Google Scholar
• FRISHMAN W, BURNS B, ATAC B et al: Novel antiplatelettherapies for treatment of patients with ischaemic heart disease: inhibitors of the platelet glycoprotein Ilb/IIIa integrin receptor. Am. Heart J. (1995) 130:877–892.
   PubMed Web of Science ®Google Scholar
• ISIS-2 (SECOND INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: Randomised trial of intravenous streptokinase, oral aspirin, both or nei-ther among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet (1998)349–360.
   PubMedGoogle Scholar
• ••Established aspirin therapy as crucial in all patients withAMI.
   Google Scholar
• RODERICK PJ, WILKES HC, MEADE TW: The gastrointes-tinal toxicity of aspirin: an overview of randomised control trials. Br. J. Clin. Pharmacol (1993) 35:219–226.
   PubMed Web of Science ®Google Scholar
• HELGASON CM, BOLIN KM, HOFF JA et al.: Development of aspirin resistance in persons with previous ischemic stroke. Stroke (1994) 25:2331–2336.
   PubMed Web of Science ®Google Scholar
• •Demonstrated differential platelet inhibition between pa-tients and in individual patients at different time frames with standard aspirin doses.
   Google Scholar
• HENNEKENS CH, EBERLEIN K, FOR THE PHYSICIANS' HEALTH STUDY RESEARCH GROUP: A randomised trial of aspirin and a-carotene amongst US physicians. Prey. Med. (1985) 14:165–168.
   PubMed Web of Science ®Google Scholar
• SCHOMIG A, NEUMANN F, KASTRATI A et al.: Random-ized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. New Engl. J. Med. (1996) 334:1084–1089.
   PubMed Web of Science ®Google Scholar
• HALL P, NAKAMURA S, MAIELLO L et al.: A randomized comparison of combined ticlopidine and aspirin ther-apy versus aspirin therapy alone after successful in-travascular ultrasound-guided stent implantation. Circulation (1996) 93:215–222.
   PubMed Web of Science ®Google Scholar
• GOODS CM, AL-SHAIBI K F, LIU MW et al.: Comparison of aspirin alone versus aspirin plus ticlopidine after coronary stenting. Am. J. Cardiol. (1996) 78:1042–1044.
   PubMed Web of Science ®Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMed Web of Science ®Google Scholar
• •Only trial of a well-tolerated oral antiplatelet agent to show improved efficacy over aspirin in atherosclerotic vascular disease.
   Google Scholar
• Antithrombotics. LMS R D PROFILES ADIS Press. Quarter1(1997).
   Google Scholar
• BERKOWITZ SD, HARRINGTON RA, RUND MM, TCHENGJE: Acute profound thrombocytopenia after c7E3 FAB (Abciximab) therapy. Circulation (1997) 95:809–813.
   PubMed Web of Science ®Google Scholar
• PHILLIPS D R, TENG W, ARFSTEN A et al.: Effect of Ca2+ on GP lib-IIIa interactions with integrilin: enhanced GP Ilb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized in plasma anticoagulated with citrate. Circulation (1997) 96:1488–1494.
   PubMed Web of Science ®Google Scholar
• THE EPIC INVESTIGATORS: Use of a monoclonal anti- body directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New Engl. J. Med. (1994) 330:956–961.
   PubMed Web of Science ®Google Scholar
• ••First large trial to demonstrate clinical efficacy of glycopro-tein IIb/IIIa receptor antagonists, and only trial to have shown reduction in restenosis post-PTCA with any pharma-cological agent.
   Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoprotein Ilb/IIIa receptor blockade and low-dose heparin dur-ing percutaneous coronary revascularisation. New Engl. J Med. (1997) 336:1689–1696.
   PubMed Web of Science ®Google Scholar
• ••Demonstrated that high bleeding rates seen in the EPIC trialcould be avoided by modulation of heparin dose.
   Google Scholar
• THE CAPTURE INVESTIGATORS: Randomised placebo-controlled trial of abciximab before and during coro-nary intervention in refractory unstable angina: the CAPTURE study. Lancet. (1997) 349:1429–1435.
   PubMed Web of Science ®Google Scholar
• FERGUSON JJ: Meeting highlights of the European Soci-ety of Cardiology. Circulation (1997) 96:3818–3821.
   Web of Science ®Google Scholar
• WHITE HD: The PRISM study. 46th Annual Scientific Ses-sion of the American College of Cardiology. Anaheim, USA (March 1997).
   Google Scholar
• THEROUX P: The PRISM-PLUS study. 46th Annual Scien-tific Session of the American College of Cardiology. Anaheim, USA (March 1997).
   Google Scholar
• THEROUX P, KOUZ S, ROY L et al.: Platelet membrane re-ceptor glycoprotein Ilb/IIIa antagonism in unstable angina. The Canadian lamifiban study. Circulation (1996) 94:899–905.
   PubMed Web of Science ®Google Scholar
• CANNON CP, MCCABE CH, BORZAK S et al. FOR THE TIMI12 INVESTIGATORS: Randomized trial of an oral platelet glycoprotein llb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Circulation (1998) 97:340–349.
   PubMed Web of Science ®Google Scholar
• BOZZA PT, PAYNE JL, MORHAM SG et al.: Leukocyte lipid body formation and eicosanoid generation: cyclooxy-genase independent inhibition by aspirin. Proc. Natl. Acad. Sci. USA (1996) 93:11091–11096.
   PubMed Web of Science ®Google Scholar
• FIBRINOLYTIC THERAPY TRIALISTS' (FTT) COLLABORA-TIVE GROUP: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity re-sults from all randomised trials of more than 1000 pa-tients. Lancet (1994) 343:311–322.
   PubMed Web of Science ®Google Scholar
• THE GUSTO ANGIOGRAPHIC INVESTIGATORS: The ef-fects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. New Engl. J. Med. (1993) 329:1615–1622.
   PubMed Web of Science ®Google Scholar
• KLEIMAN NS, OHMAN EM, CALIFF RM et al: Profound in-hibition of platelet aggregation with monoclonal anti-body 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial In-farction (TAMO 8 pilot study. J. Am. Coll. Cardiol. (1993) 22:381–389.
   Google Scholar
• OHMAN EM, KLEIMAN NS, GACHIOCH G et al. FOR THEIMPACT-AMI INVESTIGATORS: Combined accelerated tissue-plasminogen activator and platelet glycopro-tein Ilb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a random-ized, placebo-controlled, dose-ranging trial. Cir-culation (1997) 95:846–854.
   Google Scholar
• •Showed improved patency in the infarct-related artery, a surrogate for improved survival post myocardial infarction, with glycoprotein IIb/IIIa receptor blockade as an adjunct to thrombolytic therapy.
   Google Scholar